A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: Management strategies and economic impact

Supportive Care in Cancer

Volumn 18, Issue 8, 2010, Pages 1061-1079

  Jensen, S B ^a   Pedersen, A M L ^a   Vissink, A ^b   Andersen, E ^c   Brown, C G ^d   Davies, A N ^e   Dutilh, J ^f   Fulton, J S ^g   Jankovic, L ^h   Lopes, N N F ⁱ   Mello, A L S ⁱ   Muniz, L V ^j   Murdoch Kinch, C A ^k   Nair, R G ^l   Napenas J J ^m   Nogueira Rodrigues, A ^j   Saunders, D ⁿ   Stirling, B ^m   Von Bultzingslowen I ^o   Weikel, D S ^p   Elting, L S ^q   Spijkervet, F K L ^b   Brennan, M T ^m   more..

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY OF DELAWARE   (United States)

^e ROYAL MARSDEN HOSPITAL   (United Kingdom)

^f Dutilh Instituto de Reabilitação Facial e Oral   (Brazil)

^g INDIANA UNIVERSITY   (United States)

^h UNIVERSITY OF BELGRADE   (Serbia)

ⁱ FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^j Instituto de Pesquisas Oncológicas Minas Gerais IPOM   (Brazil)

^k UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

^l GRIFFITH UNIVERSITY   (Australia)

^m CAROLINAS MEDICAL CENTER   (United States)

ⁿ SUDBURY REGIONAL HOSPITAL   (Canada)

^o UNIVERSITY OF GOTHENBURG   (Sweden)

^p UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^q UNIVERSITY OF TEXAS   (United States)

more..

Author keywords

Cancer therapy; Economic impact; Management strategies; Salivary gland hypofunction; Xerostomia

Indexed keywords

AMIFOSTINE; BETHANECHOL; CEVIMELINE; LUBRICATING AGENT; MUSCARINIC AGENT; PILOCARPINE; PLACEBO;

ACUPUNCTURE; CANCER THERAPY; CLINICAL TRIAL; DIZZINESS; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ECONOMIC ASPECT; EVIDENCE BASED PRACTICE; GUSTATORY SYSTEM; HEAD AND NECK CANCER; HEADACHE; HEALTH CARE COST; HUMAN; HYPERBARIC OXYGEN; HYPOTENSION; INTENSITY MODULATED RADIATION THERAPY; LACRIMATION; MASTICATION; NASOPHARYNX CANCER; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION INJURY; REVIEW; SALIVARY GLAND DISEASE; SIDE EFFECT; SINGLE DRUG DOSE; SUBMANDIBULAR GLAND; SUBSTITUTION THERAPY; SWEATING; SYSTEMATIC REVIEW; URINARY FREQUENCY; VASODILATATION; VOMITING; XEROSTOMIA;

HUMANS; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; RADIOTHERAPY, INTENSITY-MODULATED; SALIVARY GLAND DISEASES; XEROSTOMIA;

EID: 84755161651     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-010-0837-6     Document Type: Review

References (154)

1. Jensen SB, Pedersen A M L, Vissink A, Andersen E, Brown CG, Davies AN, Dutilh J, Fulton JS, Jankovic L, Lopes N N F, Mello A L S, Muniz LV, Murdoch-Kinch CA, Nair RG, Napeñas JJ, Nogueira-Rodrigues A, Saunders D, Stirling B, von Bültzingslöwen I, Weikel DS, Elting LS, Spijkervet F K L, Brennan MT (2010) A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life. Support Care Cancer doi:10.1007/s00520-010-0827-8
2. National Institutes of Health Consensus Development Conference Consensus Statement (1989) Oral complications of cancer therapies: diagnosis, prevention, and treatment. Natl Inst Health Consens Dev Conf Consens Statement 7:1-11
3. National Institutes of Health Consensus Development Conference. Oral complications of cancer therapies: diagnosis, prevention, and treatment. Bethesda, MD, USA, April 17-19, 1989 (1990) NCI Monogr 9:1-184
4. Abok K, Brunk U, Jung B, Ericsson J (1984) Morphologic and histochemical studies on the differing radiosensitivity of ductular and acinar cells of the rat submandibular gland. Virchows Arch B Cell Pathol Incl Mol Pathol 45:443-460
5. Norberg LE, Forsberg B (1987) Alpha-adrenergic stimulation and radiosensitivity on the rat submaxillary gland. ORL J Otorhinolaryngol Relat Spec 49:302-313
6. Norberg LE, Lundquist PG (1989) Aspects of salivary gland radiosensitivity: effects of sialagogues and irradiation. Arch Oto-Rhino-Laryngol 246:200-204
7. Greenspan D, Daniels TE (1987) Effectiveness of pilocarpine in postradiation xerostomia. Cancer 59:1123-1125
8. Wolff A, Atkinson JC, Macynski AA, Fox PC (1990) Oral complications of cancer therapies. Pretherapy interventions to modify salivary dysfunction. NCI Monogr 87-90
9. Utley JF, Marlowe C, Waddell WJ (1976) Distribution of 35S-labeled WR-2721 in normal and malignant tissues of the mouse 1, 2. Radiat Res 68:284-291
10. Sodicoff M, Conger AD, Trepper P, Pratt NE (1978) Short-term radioprotective effects of WR-2721 on the rat parotid glands. Radiat Res 75:317-326 (Pubitemid 8392318)
11. Sodicoff M, Conger AD, Pratt NE, Trepper P (1978) Radioprotection by WR-2721 against long-term chronic damage to the rat parotid gland. Radiat Res 76:172-179
12. Takahashi I, Nagai T, Miyaishi K, Maehara Y, Niibe H (1986) Clinical study of the radioprotective effects of Amifostine (YM-08310, WR-2721) on chronic radiation injury. Int J Radiat Oncol Biol Phys 12:935-938
13. Matzker J, Schreiber J (1972) Synthetic saliva in the treatment of hyposialies, especially in radiation sialadenitis. Z Laryngol Rhinol Otol 51:422-428
14. Shannon IL, McCrary BR, Starcke EN (1977) A saliva substitute for use by xerostomic patients undergoing radiotherapy to the head and neck. Oral Surg Oral Med Oral Pathol 44:656-661
15. 's Gravenmade EJ, Roukema PA, Panders AK (1974) The effect of mucin-containing artificial saliva on severe xerostomia. Int J Oral Surg 3:435-439
16. Vissink A, 's Gravenmade EJ, Panders AK, Vermey A, Petersen JK, Visch LL, Schaub RM (1983) A clinical comparison between commercially available mucin-and CMC-containing saliva substitutes. Int J Oral Surg 12:232-238
17. Visch LL, 's Gravenmade EJ, Schaub RM, Van Putten WL, Vissink A (1986) A double-blind crossover trial of CMC-and mucin-containing saliva substitutes. Int J Oral Maxillofac Surg 15:395-400
18. Duxbury AJ, Thakker NS, Wastell DG (1989) A double-blind cross-over trial of a mucin-containing artificial saliva. Br Dent J 166:115-120
19. Vissink A, Schaub RM, van Rijn LJ, 's Gravenmade EJ, Panders AK, Vermey A (1987) The efficacy of mucin-containing artificial saliva in alleviating symptoms of xerostomia. Gerodontology 6:95-101
20. Vissink A, Waterman HA, 's Gravenmade EJ, Panders AK, Vermey A (1984) Rheological properties of saliva substitutes containing mucin, carboxymethylcellulose or polyethylenoxide. J Oral Pathol 13:22-28
21. Vissink A, De Jong HP, Busscher HJ, Arends J, 's Gravenmade EJ (1986) Wetting properties of human saliva and saliva substitutes. J Dent Res 65:1121-1124
22. Brennan MT, Elting LS, Spijkervet F K L (2010) Systematic reviews of oral complications from cancer therapies, Oral Care Study Group, MASCC/ISOO: Methodology and quality of the literature. Support Care Cancer (in press)
23. Baccaglini L, Brennan MT, Lockhart PB, Patton LL (2007) World Workshop on Oral Medicine IV: process and methodology for systematic review and developing management recommendations. Reference manual for management recommendations writing committees. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 103 (Suppl): S3-S19
24. Louis CU, Paulino AC, Gottschalk S, Bertuch AA, Chintagumpala M, Heslop HE, Russell HV (2007) A single institution experience with pediatric nasopharyngeal carcinoma: high incidence of toxicity associated with platinum-based chemotherapy plus IMRT. J Pediatr Hematol Oncol 29:500-505
25. Chao KS, Deasy JO, Markman J, Haynie J, Perez CA, Purdy JA, Low DA (2001) A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensitymodulated or three-dimensional radiation therapy: initial results. Int J Radiat Oncol Biol Phys 49:907-916
26. Chao KS, Majhail N, Huang CJ, Simpson JR, Perez CA, Haughey B, Spector G (2001) Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: a comparison with conventional techniques. Radiother Oncol 61:275-280
27. Eisbruch A, Kim HM, Terrell JE, Marsh LH, Dawson LA, Ship JA (2001) Xerostomia and its predictors following parotidsparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys 50:695-704
28. Amosson CM, Teh BS, Van TJ, Uy N, Huang E, Mai WY, Frolov A, Woo SY, Chiu JK, Carpenter LS, Lu HH, Grant WH III, Butler EB (2003) Dosimetric predictors of xerostomia for head-and-neck cancer patients treated with the smart (simultaneous modulated accelerated radiation therapy) boost technique. Int J Radiat Oncol Biol Phys 56:136-144
29. Chao KS, Ozyigit G, Blanco AI, Thorstad WL, Deasy JO, Haughey BH, Spector GJ, Sessions DG (2004) Intensitymodulated radiation therapy for oropharyngeal carcinoma: impact of tumor volume. Int J Radiat Oncol Biol Phys 59:43-50
30. Lu TX, Mai WY, Teh BS, Zhao C, Han F, Huang Y, Deng XW, Lu LX, Huang SM, Zeng ZF, Lin CG, Lu HH, Chiu JK, Carpenter LS, Grant WH III, Woo SY, Cui NJ, Butler EB (2004) Initial experience using intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 58:682-687
31. Jabbari S, Kim HM, Feng M, Lin A, Tsien C, Elshaikh M, Terrel JE, Murdoch-Kinch C, Eisbruch A (2005) Matched case-control study of quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head-and-neck cancer: initial report. Int J Radiat Oncol Biol Phys 63:725-731
32. Ng MK, Porceddu SV, Milner AD, Corry J, Hornby C, Hope G, Rischin D, Peters LJ (2005) Parotid-sparing radiotherapy: does it really reduce xerostomia? Clin Oncol (R Coll Radiol) 17:610-617
33. Nishimura Y, Nakamatsu K, Shibata T, Kanamori S, Koike R, Okumura M, Suzuki M (2005) Importance of the initial volume of parotid glands in xerostomia for patients with head and neck cancers treated with IMRT. Jpn J Clin Oncol 35:375-379
34. Pacholke HD, Amdur RJ, Morris CG, Li JG, Dempsey JF, Hinerman RW, Mendenhall WM (2005) Late xerostomia after intensity-modulated radiation therapy versus conventional radiotherapy. Am J Clin Oncol 28:351-358
35. Rosenbluth BD, Serrano V, Happersett L, Shaha AR, Tuttle RM, Narayana A, Wolden SL, Rosenzweig KE, Chong LM, Lee NY (2005) Intensity-modulated radiation therapy for the treatment of nonanaplastic thyroid cancer. Int J Radiat Oncol Biol Phys 63:1419-1426
36. Hsiung CY, Ting HM, Huang HY, Lee CH, Huang EY, Hsu HC (2006) Parotid-sparing intensity-modulated radiotherapy (IMRT) for nasopharyngeal carcinoma: preserved parotid function after IMRT on quantitative salivary scintigraphy, and comparison with historical data after conventional radiotherapy. Int J Radiat Oncol Biol Phys 66:454-461
37. Lee NY, de Arruda FF, Puri DR, Wolden SL, Narayana A, Mechalakos J, Venkatraman ES, Kraus D, Shaha A, Shah JP, Pfister DG, Zelefsky MJ (2006) A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 66:966-974
38. Meirovitz A, Murdoch-Kinch CA, Schipper M, Pan C, Eisbruch A (2006) Grading xerostomia by physicians or by patients after intensity-modulated radiotherapy of head-and-neck cancer. Int J Radiat Oncol Biol Phys 66:445-453
39. Nangia S, Chufal KS, Arivazhagan V, Srinivas P, Tyagi A, Ghosh D (2006) Compensator-based intensity-modulated radiotherapy in head and neck cancer: our experience in achieving dosimetric parameters and their clinical correlation. Clin Oncol (R Coll Radiol) 18:485-492
40. Pow EH, Kwong DL, McMillan AS, Wong MC, Sham JS, Leung LH, Leung WK (2006) Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 66:981-991
41. Vosmik M, Odrazka K, Dolezel M, Vaculikova M, Kordac P, Zouhar M, Petera J, Jansa J, Zoul Z, Paluska P, Vokurka J (2006) IMRT with the use of simultaneous integrated boost in treatment of head and neck cancer: acute toxicity evaluation. Acta Medica (Hradec Kralove) 49:167-173
42. Wendt TG, Abbasi-Senger N, Salz H, Pinquart I, Koscielny S, Przetak SM, Wiezorek T (2006) 3D-conformal-intensity modulated radiotherapy with compensators for head and neck cancer: clinical results of normal tissue sparing. Radiat Oncol 1:18
43. Wolden SL, Chen WC, Pfister DG, Kraus DH, Berry SL, Zelefsky MJ (2006) Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the Memorial Sloan-Kettering experience. Int J Radiat Oncol Biol Phys 64:57-62
44. Daly ME, Lieskovsky Y, Pawlicki T, Yau J, Pinto H, Kaplan M, Fee WE, Koong A, Goffinet DR, Xing L, Le QT (2007) Evaluation of patterns of failure and subjective salivary function in patients treated with intensity modulated radiotherapy for head and neck squamous cell carcinoma. Head Neck 29:211-220
45. Fang FM, Tsai WL, Chen HC, Hsu HC, Hsiung CY, Chien CY, Ko SF (2007) Intensity-modulated or conformal radiotherapy improves the quality of life of patients with nasopharyngeal carcinoma: comparisons of four radiotherapy techniques. Cancer 109:313-321
46. Graff P, Lapeyre M, Desandes E, Ortholan C, Bensadoun RJ, Alfonsi M, Maingon P, Giraud P, Bourhis J, Marchesi V, Mege A, Peiffert D (2007) Impact of intensity-modulated radiotherapy on health-related quality of life for head and neck cancer patients: matched-pair comparison with conventional radiotherapy. Int J Radiat Oncol Biol Phys 67:1309-1317
47. Kam MK, Leung SF, Zee B, Chau RM, Suen JJ, Mo F, Lai M, Ho R, Cheung KY, Yu BK, Chiu SK, Choi PH, Teo PM, Kwan WH, Chan AT (2007) Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol 25:4873-4879
48. Munter MW, Hoffner S, Hof H, Herfarth KK, Haberkorn U, Rudat V, Huber P, Debus J, Karger CP (2007) Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without amifostine. Int J Radiat Oncol Biol Phys 67:651-659
49. Rades D, Fehlauer F, Wroblesky J, Albers D, Schild SE, Schmidt R (2007) Prognostic factors in head-and-neck cancer patients treated with surgery followed by intensity-modulated radiotherapy (IMRT), 3D-conformal radiotherapy, or conventional radiotherapy. Oral Oncol 43:535-543
50. Anand AK, Chaudhoory AR, Shukla A, Negi PS, Sinha SN, Babu AA, Munjal RK, Dewan AK, Kumar K, Doval DC, Vaid AK (2008) Favourable impact of intensity-modulated radiation therapy on chronic dysphagia in patients with head and neck cancer. Br J Radiol 81:865-871
51. Huang K, Xia P, Chuang C, Weinberg V, Glastonbury CM, Eisele DW, Lee NY, Yom SS, Phillips TL, Quivey JM (2008) Intensity-modulated chemoradiation for treatment of stage III and IV oropharyngeal carcinoma: the University of California-San Francisco experience. Cancer 113:497-507
52. Klem ML, Mechalakos JG, Wolden SL, Zelefsky MJ, Singh B, Kraus D, Shaha A, Shah J, Pfister DG, Lee NY (2008) Intensitymodulated radiotherapy for head and neck cancer of unknown primary: toxicity and preliminary efficacy. Int J Radiat Oncol Biol Phys 70:1100-1107
53. Madani I, Vakaet L, Bonte K, Boterberg T, De NW (2008) Intensity-modulated radiotherapy for cervical lymph node metastases from unknown primary cancer. Int J Radiat Oncol Biol Phys 71:1158-1166
54. Rusthoven KE, Raben D, Ballonoff A, Kane M, Song JI, Chen C (2008) Effect of radiation techniques in treatment of oropharynx cancer. Laryngoscope 118:635-639
55. Seung S, Bae J, Solhjem M, Bader S, Gannett D, Hansen EK, Louie J, Underhill K, Cha C (2008) Intensity-modulated radiotherapy for head-and-neck cancer in the community setting. Int J Radiat Oncol Biol Phys 72:1075-1081
56. van Rij CM, Oughlane-Heemsbergen WD, Ackerstaff AH, Lamers EA, Balm AJ, Rasch CR (2008) Parotid gland sparing IMRT for head and neck cancer improves xerostomia related quality of life. Radiat Oncol 3:41
57. Eisbruch A, Ten Haken RK, Kim HM, Marsh LH, Ship JA (1999) Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys 45:577-587
58. Lin A, Kim HM, Terrell JE, Dawson LA, Ship JA, Eisbruch A (2003) Quality of life after parotid-sparing IMRT for head-andneck cancer: a prospective longitudinal study. Int J Radiat Oncol Biol Phys 57:61-70
59. Blanco AI, Chao KS, El Naqa I, Franklin GE, Zakarian K, Vicic M, Deasy JO (2005) Dose-volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy. Int J Radiat Oncol Biol Phys 62:1055-1069
60. Saarilahti K, Kouri M, Collan J, Hamalainen T, Atula T, Joensuu H, Tenhunen M (2005) Intensity modulated radiotherapy for head and neck cancer: evidence for preserved salivary gland function. Radiother Oncol 74:251-258
61. de Arruda FF, Puri DR, Zhung J, Narayana A, Wolden S, Hunt M, Stambuk H, Pfister D, Kraus D, Shaha A, Shah J, Lee NY (2006) Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys 64:363-373 (Pubitemid 43083420)
62. Liu WS, Lee SP, Lee JK, Su MC, Chen GD, Lee HS, Lee H (2006) Factors influencing the parotid function in nasopharyngeal carcinoma treated with parotid-sparing radiotherapy. Jpn J Clin Oncol 36:626-631 (Pubitemid 44697555)
63. Liu WS, Kuo HC, Lin JC, Su MC, Lee JK, Chou MJ, Chou MC, Lee H (2006) Assessment of salivary function change in nasopharyngeal carcinoma treated by parotid-sparing radiotherapy. Cancer J 12:494-500 (Pubitemid 46026198)
64. Li Y, Taylor JM, Ten Haken RK, Eisbruch A (2007) The impact of dose on parotid salivary recovery in head and neck cancer patients treated with radiation therapy. Int J Radiat Oncol Biol Phys 67:660-669
65. Sultanem K, Shu HK, Xia P, Akazawa C, Quivey JM, Verhey LJ, Fu KK (2000) Three-dimensional intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys 48:711-722
66. Kam MK, Teo PM, Chau RM, Cheung KY, Choi PH, Kwan WH, Leung SF, Zee B, Chan AT (2004) Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience. Int J Radiat Oncol Biol Phys 60:1440-1450
67. Munter MW, Karger CP, Hoffner SG, Hof H, Thilmann C, Rudat V, Nill S, Wannenmacher M, Debus J (2004) Evaluation of salivary gland function after treatment of head-and-neck tumors with intensity-modulated radiotherapy by quantitative pertechnetate scintigraphy. Int J Radiat Oncol Biol Phys 58:175-184
68. Anand AK, Jain J, Negi PS, Chaudhoory AR, Sinha SN, Choudhury PS, Kumar R, Munjal RK (2006) Can dose reduction to one parotid gland prevent xerostomia?-A feasibility study for locally advanced head and neck cancer patients treated with intensity-modulated radiotherapy. Clin Oncol (R Coll Radiol) 18:497-504
69. Lee NY, O'Meara W, Chan K, la-Bianca C, Mechalakos JG, Zhung J, Wolden SL, Narayana A, Kraus D, Shah JP, Pfister DG (2007) Concurrent chemotherapy and intensity-modulated radiotherapy for locoregionally advanced laryngeal and hypopharyngeal cancers. Int J Radiat Oncol Biol Phys 69:459-468
70. Roesink JM, Moerland MA, Battermann JJ, Hordijk GJ, Terhaard CH (2001) Quantitative dose-volume response analysis of changes in parotid gland function after radiotherapy in the head-and-neck region. Int J Radiat Oncol Biol Phys 51:938-946
71. Saarilahti K, Kouri M, Collan J, Kangasmaki A, Atula T, Joensuu H, Tenhunen M (2006) Sparing of the submandibular glands by intensity modulated radiotherapy in the treatment of head and neck cancer. Radiother Oncol 78:270-275
72. Murdoch-Kinch CA, Kim HM, Vineberg KA, Ship JA, Eisbruch A (2008) Dose-effect relationships for the submandibular salivary glands and implications for their sparing by intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys 72:373-382
73. Lin SC, Jen YM, Chang YC, Lin CC (2008) Assessment of xerostomia and its impact on quality of life in head and neck cancer patients undergoing radiotherapy, and validation of the Taiwanese version of the xerostomia questionnaire. J Pain Symptom Manage 36:141-148
74. Brizel DM, Wasserman TH, Henke M, Strnad V, Rudat V, Monnier A, Eschwege F, Zhang J, Russell L, Oster W, Sauer R (2000) Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18:3339-3345
75. Wasserman TH, Brizel DM, Henke M, Monnier A, Eschwege F, Sauer R, Strnad V (2005) Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and-neck cancer: 2-year follow-up of a prospective, randomized, phase III trial. Int J Radiat Oncol Biol Phys 63:985-990
76. Hensley ML, Hagerty KL, Kewalramani T, Green DM, Meropol NJ, Wasserman TH, Cohen GI, Emami B, Gradishar WJ, Mitchell RB, Thigpen JT, Trotti A III, von Hoff D, Schuchter LM (2009) American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol 27:127-145
77. Vacha P, Fehlauer F, Mahlmann B, Marx M, Hinke A, Sommer K, Richter E, Feyerabend T (2003) Randomized phase III trial of postoperative radiochemotherapy+/-amifostine in head and neck cancer. Is there evidence for radioprotection? Strahlenther Onkol 179:385-389
78. Antonadou D, Pepelassi M, Synodinou M, Puglisi M, Throuvalas N (2002) Prophylactic use of amifostine to prevent radiochemotherapyinduced mucositis and xerostomia in head-and-neck cancer. Int J Radiat Oncol Biol Phys 52:739-747
79. Karacetin D, Yucel B, Leblebicioglu B, Aksakal O, Maral O, Incekara O (2004) A randomized trial of amifostine as radioprotector in the radiotherapy of head and neck cancer. J BUON 9:23-26
80. Buntzel J, Glatzel M, Mucke R, Micke O, Bruns F (2007) Influence of amifostine on late radiation-toxicity in head and neck cancer-a follow-up study. Anticancer Res 27:1953-1956
81. Kouloulias VE, Kouvaris JR, Kokakis JD, Kostakopoulos A, Mallas E, Metafa A, Vlahos LJ (2004) Impact on cytoprotective efficacy of intermediate interval between amifostine administration and radiotherapy: a retrospective analysis. Int J Radiat Oncol Biol Phys 59:1148-1156
82. Buentzel J, Micke O, Adamietz IA, Monnier A, Glatzel M, de Vries A (2006) Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebocontrolled phase III study. Int J Radiat Oncol Biol Phys 64:684-691
83. Bohuslavizki KH, Klutmann S, Brenner W, Kroger S, Buchert R, Bleckmann C, Mester J, Henze E, Clausen M (1999) Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment. Results of a double-blinded, placebo-controlled study in patients with differentiated thyroid cancer. Strahlenther Onkol 175 (Suppl 4):6-12
84. Rudat V, Meyer J, Momm F, Bendel M, Henke M, Strnad V, Grotz K, Schulte A (2000) Protective effect of amifostine on dental health after radiotherapy of the head and neck. Int J Radiat Oncol Biol Phys 48:1339-1343
85. Veerasarn V, Phromratanapongse P, Suntornpong N, Lorvidhaya V, Sukthomya V, Chitapanarux I, Tesavibul C, Swangsilpa T, Khorprasert C, Shotelersuk K, Kongthanarat Y, Panichevaluk A, Chiewvit S, Pusuwan P, Aekmahachai M, Ratchadara S, Sirilipoche S, Saengsuda Y (2006) Effect of amifostine to prevent radiotherapy-induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. J Med Assoc Thail 89:2056-2067
86. Rudat V, Munter M, Rades D, Grotz KA, Bajrovic A, Haberkorn U, Brenner W, Debus J (2008) The effect of amifostine or IMRT to preserve the parotid function after radiotherapy of the head and neck region measured by quantitative salivary gland scintigraphy. Radiother Oncol 89:71-80
87. Ozsahin M, Betz M, Matzinger O, Bron L, Luthi F, Pasche P, Azria D, Mirimanoff RO, Zouhair A (2006) Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy. Arch Otolaryngol Head Neck Surg 132:141-145
88. Law A, Kennedy T, Pellitteri P, Wood C, Christie D, Yumen O (2007) Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combinedmodality treatment for squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 69:1361-1368
89. Brizel DM, Overgaard J (2003) Does amifostine have a role in chemoradiation treatment? Lancet Oncol 4:378-381
90. Fox PC, Atkinson JC, Macynski AA, Wolff A, Kung DS, Valdez IH, Jackson W, Delapenha RA, Shiroky J, Baum BJ (1991) Pilocarpine treatment of salivary gland hypofunction and dry mouth (xerostomia). Arch Intern Med 151:1149-1152
91. Wiseman LR, Faulds D (1995) Oral pilocarpine: a review of its pharmacological properties and clinical potential in xerostomia. Drugs 49:143-155
92. Johnson JT, Ferretti GA, Nethery WJ, Valdez IH, Fox PC, Ng D, Muscoplat CC, Gallagher SC (1993) Oral pilocarpine for postirradiation xerostomia in patients with head and neck cancer. N Engl J Med 329:390-395
93. LeVeque FG, Montgomery M, Potter D, Zimmer MB, Rieke JW, Steiger BW, Gallagher SC, Muscoplat CC (1993) A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. J Clin Oncol 11:1124-1131
94. Davies AN, Singer J (1994) A comparison of artificial saliva and pilocarpine in radiation-induced xerostomia. J Laryngol Otol 108:663-665
95. Rieke JW, Hafermann MD, Johnson JT, Le Veque FG, Iwamoto R, Steiger BW, Muscoplat C, Gallagher SC (1995) Oral pilocarpine for radiation-induced xerostomia: integrated efficacy and safety results from two prospective randomized clinical trials. Int J Radiat Oncol Biol Phys 31:661-669
96. Hamlar DD, Schuller DE, Gahbauer RA, Buerki RA, Staubus AE, Hall J, Altman JS, Elzinga DJ, Martin MR (1996) Determination of the efficacy of topical oral pilocarpine for postirradiation xerostomia in patients with head and neck carcinoma. Laryngoscope 106:972-976
97. Nyarady Z, Nemeth A, Ban A, Mukics A, Nyarady J, Ember I, Olasz L (2006) A randomized study to assess the effectiveness of orally administered pilocarpine during and after radiotherapy of head and neck cancer. Anticancer Res 26:1557-1562
98. Taweechaisupapong S, Pesee M, Aromdee C, Laopaiboon M, Khunkitti W (2006) Efficacy of pilocarpine lozenge for postradiation xerostomia in patients with head and neck cancer. Aust Dent J 51:333-337
99. Chitapanarux I, Kamnerdsupaphon P, Tharavichitkul E, Sumitsawan Y, Sittitrai P, Pattarasakulchai T, Lorvidhaya V, Sukthomya V, Pukanhaphan N, Traisatit P (2008) Effect of oral pilocarpine on post-irradiation xerostomia in head and neck cancer patients: a single-center, single-blind clinical trial. J Med Assoc Thail 91:1410-1415
100. Silberstein EB (2008) Reducing the incidence of 131I-induced sialadenitis: the role of pilocarpine. J Nucl Med 49:546-549
101. Jacobs CD, van der Pas M (1996) A multicenter maintenance study of oral pilocarpine tablets for radiation-induced xerostomia. Oncology (Williston Park) 10:16-20
102. Singhal S, Powles R, Treleaven J, Rattenbury H, Mehta J (1997) Pilocarpine hydrochloride for symptomatic relief of xerostomia due to chronic graft-versus-host disease or total-body irradiation after bone-marrow transplantation for hematologic malignancies. Leuk Lymphoma 24:539-543
103. Niedermeier W, Matthaeus C, Meyer C, Staar S, Muller RP, Schulze HJ (1998) Radiation-induced hyposalivation and its treatment with oral pilocarpine. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 86:541-549
104. Horiot JC, Lipinski F, Schraub S, Maulard-Durdux C, Bensadoun RJ, Ardiet JM, Bolla M, Coscas Y, Baillet F, Coche-Dequeant B, Urbajtel M, Montbarbon X, Bourdin S, Wibault M, Alfonsi M, Calais G, Desprez P, Pene F, Lapeyre M, Vinke J, Maral J (2000) Post-radiation severe xerostomia relieved by pilocarpine: a prospective French cooperative study. Radiother Oncol 55:233-239
105. Ringash J, Warde P, Lockwood G, O'Sullivan B, Waldron J, Cummings B (2005) Postradiotherapy quality of life for headand-neck cancer patients is independent of xerostomia. Int J Radiat Oncol Biol Phys 61:1403-1407
106. Aframian DJ, Helcer M, Livni D, Markitziu A (2006) Pilocarpine for the treatment of salivary glands' impairment caused by radioiodine therapy for thyroid cancer. Oral Dis 12:297-300
107. Aframian DJ, Helcer M, Livni D, Robinson SD, Markitziu A, Nadler C (2007) Pilocarpine treatment in a mixed cohort of xerostomic patients. Oral Dis 13:88-92
108. Daniels TE, Wu AJ (2000) Xerostomia-clinical evaluation and treatment in general practice. J Calif Dent Assoc 28:933-941
109. Bernardi R, Perin C, Becker FL, Ramos GZ, Gheno GZ, Lopes LR, Pires M, Barros HM (2002) Effect of pilocarpine mouthwash on salivary flow. Braz J Med Biol Res 35:105-110
110. Valdez IH, Wolff A, Atkinson JC, Macynski AA, Fox PC (1993) Use of pilocarpine during head and neck radiation therapy to reduce xerostomia and salivary dysfunction. Cancer 71:1848-1851
111. Licht R, Kampinga HH, Coppes RP (2002) Salivary glandsparing prophylactic pilocarpine treatment has no effect on tumor regrowth after irradiation. Radiat Res 157:596-598
112. Lajtman Z, Krajina Z, Krpan D, Vincelj J, Borcic V, Popovic-Kovacic J (1999) Pilocarpine in the prevention of postirradiation xerostomia. Acta Med Croatica 54:65-67
113. Sangthawan D, Watthanaarpornchai S, Phungrassami T (2001) Randomized double blind, placebo-controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. J Med Assoc Thail 84:195-203
114. Haddad P, Karimi M (2002) A randomized, double-blind, placebo-controlled trial of concomitant pilocarpine with head and neck irradiation for prevention of radiation-induced xerostomia. Radiother Oncol 64:29-32
115. Warde P, O'Sullivan B, Aslanidis J, Kroll B, Lockwood G, Waldron J, Payne D, Bayley A, Ringash J, Kim J, Liu FF, Maxymiw W, Sprague S, Cummings BJ (2002) A phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 54:9-13
116. Fisher J, Scott C, Scarantino CW, LeVeque FG, White RL, Rotman M, Hodson DI, Meredith RF, Foote R, Bachman DG, Lee N (2003) Phase III quality-of-life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head-and-neck cancer-RTOG 97-09. Int J Radiat Oncol Biol Phys 56:832-836
117. Gornitsky M, Shenouda G, Sultanem K, Katz H, Hier M, Black M, Velly AM (2004) Double-blind randomized, placebocontrolled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 98:45-52
118. Gorsky M, Epstein JB, Parry J, Epstein MS, Le ND, Silverman S Jr (2004) The efficacy of pilocarpine and bethanechol upon saliva production in cancer patients with hyposalivation following radiation therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 97:190-195
119. Scarantino C, LeVeque F, Swann RS, White R, Schulsinger A, Hodson DI, Meredith R, Foote R, Brachman D, Lee N (2006) Effect of pilocarpine during radiation therapy: results of RTOG 97-09, a phase III randomized study in head and neck cancer patients. J Support Oncol 4:252-258
120. Burlage FR, Roesink JM, Kampinga HH, Coppes RP, Terhaard C, Langendijk JA, van LP S, MA VA (2008) Protection of salivary function by concomitant pilocarpine during radiotherapy: a double-blind, randomized, placebo-controlled study. Int J Radiat Oncol Biol Phys 70:14-22
121. Zimmerman RP, Mark RJ, Tran LM, Juillard GF (1997) Concomitant pilocarpine during head and neck irradiation is associated with decreased posttreatment xerostomia. Int J Radiat Oncol Biol Phys 37:571-575
122. Mateos JJ, Setoain X, Ferre J, Rovirosa A, Navalpotro B, Martin F, Ortega M, Lomena F, Fuster D, Pavia J, Pons F (2001) Salivary scintigraphy for assessing the protective effect of pilocarpine in head and neck irradiated
123. Chambers MS, Posner M, Jones CU, Biel MA, Hodge KM, Vitti R, Armstrong I, Yen C, Weber RS (2007) Cevimeline for the treatment of postirradiation xerostomia in patients with head and neck cancer. Int J Radiat Oncol Biol Phys 68:1102-1109 (Pubitemid 47053952)
124. Chambers MS, Jones CU, Biel MA, Weber RS, Hodge KM, Chen Y, Holland JM, Ship JA, Vitti R, Armstrong I, Garden AS, Haddad R (2007) Open-label, long-term safety study of cevimeline in the treatment of postirradiation xerostomia. Int J Radiat Oncol Biol Phys 69:1369-1376 (Pubitemid 350123574)
125. Jham BC, Teixeira IV, Aboud CG, Carvalho AL, Coelho MM, Freire AR (2007) A randomized phase III prospective trial of bethanechol to prevent radiotherapy-induced salivary gland damage in patients with head and neck cancer. Oral Oncol 43:137-142
126. Senahayake F, Piggott K, Hamilton-Miller JM (1998) A pilot study of Salix SST (saliva-stimulating lozenges) in postirradiation xerostomia. Curr Med Res Opin 14:155-159
127. Jensdottir T, Nauntofte B, Buchwald C, Hansen HS, Bardow A (2006) Effects of sucking acidic candies on saliva in unilaterally irradiated pharyngeal cancer patients. Oral Oncol 42:317-322
128. Duncan GG, Epstein JB, Tu D, El SS, Bezjak A, Ottaway J, Pater J (2005) Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis. Head Neck 27:421-428
129. Nakada K, Ishibashi T, Takei T, Hirata K, Shinohara K, Katoh S, Zhao S, Tamaki N, Noguchi Y, Noguchi S (2005) Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? J Nucl Med 46:261-266
130. Epstein JB, Emerton S, Le ND, Stevenson-Moore P (1999) A double-blind crossover trial of Oral Balance gel and Biotene toothpaste versus placebo in patients with xerostomia following radiation therapy. Oral Oncol 35:132-137
131. Shahdad SA, Taylor C, Barclay SC, Steen IN, Preshaw PM (2005) A double-blind, crossover study of Biotene Oralbalance and BioXtra systems as salivary substitutes in patients with postradiotherapy xerostomia. Eur J Cancer Care (Engl) 14:319-326
132. Nagy K, Urban E, Fazekas O, Thurzo L, Nagy E (2007) Controlled study of lactoperoxidase gel on oral flora and saliva in irradiated patients with oral cancer. J Craniofac Surg 18:1157-1164
133. Dirix P, Nuyts S, Vander Poorten V, Delaere P, Van den Bogaert W (2007) Efficacy of the BioXtra dry mouth care system in the treatment of radiotherapy-induced xerostomia. Support Care Cancer 15:1429-1436
134. Epstein JB, Stevenson-Moore P (1992) A clinical comparative trial of saliva substitutes in radiation-induced salivary gland hypofunction. Spec Care Dentist 12:21-23
135. Andersson G, Johansson G, Attstrom R, Edwardsson S, Glantz PO, Larsson K (1995) Comparison of the effect of the linseed extract Salinum and a methyl cellulose preparation on the symptoms of dry mouth. Gerodontology 12:12-17
136. Momm F, Volegova-Neher NJ, Schulte-Monting J, Guttenberger R (2005) Different saliva substitutes for treatment of xerostomia following radiotherapy. A prospective crossover study. Strahlenther Onkol 181:231-236
137. Johansson G, Andersson G, Attstrom R, Glantz PO, Larsson K (1994) The effect of Salinum on the symptoms of dry mouth: a pilot study. Gerodontology 11:46-49
138. Momm F, Guttenberger R (2002) Treatment of xerostomia following radiotherapy: does age matter? Support Care Cancer 10:505-508
139. Jellema AP, Langendijk H, Bergenhenegouwen L, van der Reijden W, Leemans R, Smeele L, Slotman BJ (2001) The efficacy of Xialine in patients with xerostomia resulting from radiotherapy for head and neck cancer: a pilot-study. Radiother Oncol 59:157-160
140. Regelink G, Vissink A, Reintsema H, Nauta JM (1998) Efficacy of a synthetic polymer saliva substitute in reducing oral complaints of patients suffering from irradiation-induced xerostomia. Quintessence Int 29:383-388
141. Jha N, Seikaly H, Harris J, Williams D, Liu R, McGaw T, Hofmann H, Robinson D, Hanson J, Barnaby P (2003) Prevention of radiation induced xerostomia by surgical transfer of submandibular salivary gland into the submental space. Radiother Oncol 66:283-289
142. Pathak KA, Bhalavat RL, Mistry RC, Deshpande MS, Bhalla V, Desai SB, Malpani BL (2004) Upfront submandibular salivary gland transfer in pharyngeal cancers. Oral Oncol 40:960-963
143. Seikaly H, Jha N, Harris JR, Barnaby P, Liu R, Williams D, McGaw T, Rieger J, Wolfaardt J, Hanson J (2004) Long-term outcomes of submandibular gland transfer for prevention of postradiation xerostomia. Arch Otolaryngol Head Neck Surg 130:956-961
144. Al-Qahtani K, Hier MP, Sultanum K, Black MJ (2006) The role of submandibular salivary gland transfer in preventing xerostomia in the chemoradiotherapy patient. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 101:753-756
145. Jha N, Seikaly H, Harris J, Williams D, Sultanem K, Hier M, Ghosh S, Black M, Butler J, Sutherland D, Kerr P, Barnaby P (2009) Phase III randomized study: oral pilocarpine versus submandibular salivary gland transfer protocol for the management of radiation-induced xerostomia. Head Neck 31:234-243
146. Johnstone PA, Peng YP, May BC, Inouye WS, Niemtzow RC (2001) Acupuncture for pilocarpine-resistant xerostomia following radiotherapy for head and neck malignancies. Int J Radiat Oncol Biol Phys 50:353-357
147. Blom M, Dawidson I, Fernberg JO, Johnson G, Angmar-Mansson B (1996) Acupuncture treatment of patients with radiation-induced xerostomia. Eur J Cancer B Oral Oncol 32 B: 182-190
148. Blom M, Lundeberg T (2000) Long-term follow-up of patients treated with acupuncture for xerostomia and the influence of additional treatment. Oral Dis 6:15-24
149. Cho JH, Chung WK, Kang W, Choi SM, Cho CK, Son CG (2008) Manual acupuncture improved quality of life in cancer patients with radiation-induced xerostomia. J Altern Complement Med 14:523-526
150. Gerlach NL, Barkhuysen R, Kaanders JH, Janssens GO, Sterk W, Merkx MA (2008) The effect of hyperbaric oxygen therapy on quality of life in oral and oropharyngeal cancer patients treated with radiotherapy. Int J Oral Maxillofac Surg 37:255-259
151. Harding SA, Hodder SC, Courtney DJ, Bryson PJ (2008) Impact of perioperative hyperbaric oxygen therapy on the quality of life of maxillofacial patients who undergo surgery in irradiated fields. Int J Oral Maxillofac Surg 37:617-624
152. Langendijk JA, Doornaert P, Verdonck-de Leeuw IM, Leemans CR, Aaronson NK, Slotman BJ (2008) Impact of late treatmentrelated toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol 26:3770-3776
153. Baum BJ, Zheng C, Cotrim AP, McCullagh L, Goldsmith CM, Brahim JS, Atkinson JC, Turner RJ, Liu S, Nikolov N, Illei GG (2009) Aquaporin-1 gene transfer to correct radiation-induced salivary hypofunction. Handb Exp Pharmacol 403-418
154. Coppes RP, van der Goot A, Lombaert IM (2009) Stem cell therapy to reduce radiation-induced normal tissue damage. Semin Radiat Oncol 19:112-121